For instance, white people are most likely to take GLP-1 drugs, more than Asian, black, Native American or Hispanic groupsin that order, with 5.1 percent of white patients with obesity on weight loss drugs compared to just 3.7 percent of Hispanic patients with obesity
There have been very few reported instances of harm directly linked to compounded GLP-1 medications, reinforcing their general safety when sourced from reputable compounding pharmacies
In general, GLP-1 agonists promote weight loss through the following two mechanisms: Suppression of appetite and cravings: These medications target the brain to curtail appetite so one can achieve satiety with small portions of food
By learning to balance potassium intake, manage hydration, and keep an open line of communication with healthcare providers, users can maintain their health more effectively